infohep news

• Pan-genotypic regimens

  US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment

  Liz Highleyman / 19 July 2017

  On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" ...

• Fibrosis

  Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors

  Michael Carter / 19 July 2017

  Over a third of people with HIV have non-alcoholic fatty liver disease (NAFLD) in the absence of hepatitis B or C, according to the results of a meta-analysis and systematic ...

• Disease course and symptoms

  HCV therapy with SVR reduces the risk of several non-liver-related diseases commonly seen in people with chronic HCV

  Michael Carter / 06 July 2017

  The risk of several non-liver complications associated with chronic hepatitis C virus (HCV) infection is reduced after interferon-based treatment that achieves a sustained virological response (SVR), investigators from the United ...

• Epidemiology

  San Francisco task force releases first hepatitis C estimates

  Liz Highleyman / 04 July 2017

  End Hep C SF, a consortium of public health workers, medical providers, advocates and people living with hepatitis C, has released the first-ever estimate of the number of people thought to be ...

• Hepatitis A

  Hepatitis A outbreak in gay and bisexual men in Europe is growing

  Keith Alcorn / 03 July 2017

  New cases of hepatitis A cases have soared in Western Europe over the past six months as a result of an epidemic in gay and bisexual men, the European Centre ...